Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, secukinumab i ustekinumab: per al tractament de l'artritis psoriàsica activa en pacients adults quan la resposta als fàrmacs antireumàtics modificadors de la malaltia ha estat inadequada
Abstract
Psoriatic arthritis (APs) is a chronic inflammatory disease of the musculoskeletal system associated with psoriasis. It is a heterogeneous disease with a wide variety of clinical manifestations: peripheral arthritis, axial affectation, entesitis, dactilitis and skin and unguial affectation. It can also present other extraarticular affections such as inflammatory bowel disease and ocular manifestations such as uveitis.
In the APs, the type of predominant manifestation (peripheral, axial, mixed, entesitic) presented by the patient determines the type of pharmacological and clinical monitoring approach .:
Keywords
Psoriatic arthritis; Biological drugs: Adult patients
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, secukinumab i ustekinumab: per al tractament de l'artritis psoriàsica activa en pacients adults quan la resposta als fàrmacs antireumàtics modificadors de la malaltia ha estat inadequada. Barcelona: Servei Català de la Salut; 2018.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4189This item appears in following collections
The following license files are associated with this item: